{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T15:46:39Z","timestamp":1763480799089,"version":"3.37.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872182, 81802685"],"award-info":[{"award-number":["81872182, 81802685"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00280-024-04695-z","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T12:02:20Z","timestamp":1725537740000},"page":"599-613","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Avermectin B1 mediates antitumor activity and induces autophagy in osteosarcoma through the AMPK\/ULK1 signaling pathway"],"prefix":"10.1007","volume":"94","author":[{"given":"Xiang","family":"Fei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaohui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghui","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongdong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingcheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"issue":"12","key":"4695_CR1","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1016\/j.annonc.2021.08.1995","volume":"32","author":"SJ Strauss","year":"2021","unstructured":"Strauss SJ, Frezza AM, Abecassis N, Bajpai J, Bauer S, Biagini R et al (2021) Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 32(12):1520\u20131536. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1995","journal-title":"Ann Oncol"},{"issue":"5","key":"4695_CR2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/07357907.2020.1768401","volume":"38","author":"LR Sadykova","year":"2020","unstructured":"Sadykova LR, Ntekim AI, Muyangwa-Semenova M, Rutland CS, Jeyapalan JN, Blatt N et al (2020) Epidemiology and risk factors of Osteosarcoma. Cancer Invest 38(5):259\u2013269. https:\/\/doi.org\/10.1080\/07357907.2020.1768401","journal-title":"Cancer Invest"},{"issue":"1","key":"4695_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/14737140.2018.1413939","volume":"18","author":"DJ Harrison","year":"2018","unstructured":"Harrison DJ, Geller DS, Gill JD, Lewis VO, Gorlick R (2018) Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther 18(1):39\u201350. https:\/\/doi.org\/10.1080\/14737140.2018.1413939","journal-title":"Expert Rev Anticancer Ther"},{"issue":"22","key":"4695_CR4","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1056\/NEJMra2103423","volume":"385","author":"PS Meltzer","year":"2021","unstructured":"Meltzer PS, Helman LJ (2021) New Horizons in the Treatment of Osteosarcoma. N Engl J Med 385(22):2066\u20132076. https:\/\/doi.org\/10.1056\/NEJMra2103423","journal-title":"N Engl J Med"},{"issue":"2","key":"4695_CR5","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1200\/jco.2017.75.1743","volume":"36","author":"JS Whelan","year":"2018","unstructured":"Whelan JS, Davis LE (2018) Osteosarcoma, Chondrosarcoma, and Chordoma. J Clin Oncol 36(2):188\u2013193. https:\/\/doi.org\/10.1200\/jco.2017.75.1743","journal-title":"J Clin Oncol"},{"key":"4695_CR6","doi-asserted-by":"publisher","unstructured":"Lilienthal I, Herold N (2020) Targeting Molecular mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: a review of current and future strategies. Int J Mol Sci 21(18). https:\/\/doi.org\/10.3390\/ijms21186885","DOI":"10.3390\/ijms21186885"},{"key":"4695_CR7","doi-asserted-by":"crossref","unstructured":"Gr\u00fcnewald TG, Alonso M, Avnet S, Banito A, Burdach S, Cidre-Aranaz F et al (2020) Sarcoma treatment in the era of molecular medicine. EMBO Mol Med 12(11):e11131. https:\/\/doi.org\/10.15252\/emmm201911131","DOI":"10.15252\/emmm.201911131"},{"key":"4695_CR8","doi-asserted-by":"crossref","unstructured":"Sayles LC, Breese MR, Koehne AL, Leung SG, Lee AG, Liu HY et al (2019) Genome-informed targeted therapy for Osteosarcoma. Cancer Discov 9(1):46\u201363. https:\/\/doi.org\/10.1158\/2159\u20138290.CD-17-1152","DOI":"10.1158\/2159-8290.CD-17-1152"},{"issue":"3","key":"4695_CR9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1128\/aac.15.3.361","volume":"15","author":"RW Burg","year":"1979","unstructured":"Burg RW, Miller BM, Baker EE, Birnbaum J, Currie SA, Hartman R et al (1979) Avermectins, new family of potent anthelmintic agents: producing organism and fermentation. Antimicrob Agents Chemother 15(3):361\u2013367. https:\/\/doi.org\/10.1128\/aac.15.3.361","journal-title":"Antimicrob Agents Chemother"},{"issue":"1\u20133","key":"4695_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejphar.2004.08.009","volume":"501","author":"VA Drinyaev","year":"2004","unstructured":"Drinyaev VA, Mosin VA, Kruglyak EB, Novik TS, Sterlina TS, Ermakova NV et al (2004) Antitumor effect of avermectins. Eur J Pharmacol 501(1\u20133):19\u201323. https:\/\/doi.org\/10.1016\/j.ejphar.2004.08.009","journal-title":"Eur J Pharmacol"},{"issue":"1\u20133","key":"4695_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejphar.2004.03.067","volume":"493","author":"YN Korystov","year":"2004","unstructured":"Korystov YN, Ermakova NV, Kublik LN, Levitman M, Shaposhnikova VV, Mosin VA et al (2004) Avermectins inhibit multidrug resistance of tumor cells. Eur J Pharmacol 493(1\u20133):57\u201364. https:\/\/doi.org\/10.1016\/j.ejphar.2004.03.067","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"4695_CR12","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.toxlet.2009.10.021","volume":"192","author":"YJ Sun","year":"2010","unstructured":"Sun YJ, Long DX, Li W, Hou WY, Wu YJ, Shen JZ (2010) Effects of avermectins on neurite outgrowth in differentiating mouse neuroblastoma N2a cells. Toxicol Lett 192(2):206\u2013211. https:\/\/doi.org\/10.1016\/j.toxlet.2009.10.021","journal-title":"Toxicol Lett"},{"key":"4695_CR13","doi-asserted-by":"crossref","unstructured":"Kwon YJ, Petrie K, Leibovitch BA, Zeng L, Mezei M, Howell L et al (2015) Selective inhibition of SIN3 Corepressor with avermectins as a Novel Therapeutic Strategy in Triple-negative breast Cancer. Mol Cancer Ther 14(8):1824\u20131836. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0980-T","DOI":"10.1158\/1535-7163.MCT-14-0980-T"},{"key":"4695_CR14","doi-asserted-by":"publisher","unstructured":"Vargas JNS, Hamasaki M, Kawabata T, Youle RJ, Yoshimori T (2023) The mechanisms and roles of selective autophagy in mammals. Nat Rev Mol Cell Biol 24(3):167\u2013185. https:\/\/doi.org\/10.1038\/s41580-022-00542-2","DOI":"10.1038\/s41580-022-00542-2"},{"issue":"5","key":"4695_CR15","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41556-018-0092-5","volume":"20","author":"N Mizushima","year":"2018","unstructured":"Mizushima N (2018) A brief history of autophagy from cell biology to physiology and disease. Nat Cell Biol 20(5):521\u2013527. https:\/\/doi.org\/10.1038\/s41556-018-0092-5","journal-title":"Nat Cell Biol"},{"key":"4695_CR16","doi-asserted-by":"publisher","unstructured":"Debnath J, Gammoh N, Ryan KM Autophagy and autophagy-related pathways in cancer. Nat Rev Mol Cell Biol 2023:1\u201316 https:\/\/doi.org\/10.1038\/s41580-023-00585-z","DOI":"10.1038\/s41580-023-00585-z"},{"issue":"5","key":"4695_CR17","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.cmet.2017.04.004","volume":"25","author":"AC Kimmelman","year":"2017","unstructured":"Kimmelman AC, White E (2017) Autophagy and Tumor Metabolism. Cell Metab 25(5):1037\u20131043. https:\/\/doi.org\/10.1016\/j.cmet.2017.04.004","journal-title":"Cell Metab"},{"issue":"12","key":"4695_CR18","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1080\/15548627.2016.1231494","volume":"12","author":"K Wang","year":"2016","unstructured":"Wang K, Gao W, Dou Q, Chen H, Li Q, Nice EC et al (2016) Ivermectin induces PAK1-mediated cytostatic autophagy in breast cancer. Autophagy 12(12):2498\u20132499. https:\/\/doi.org\/10.1080\/15548627.2016.1231494","journal-title":"Autophagy"},{"issue":"15","key":"4695_CR19","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1158\/0008-5472.Can-15-2887","volume":"76","author":"Q Dou","year":"2016","unstructured":"Dou Q, Chen HN, Wang K, Yuan K, Lei Y, Li K et al (2016) Ivermectin induces Cytostatic Autophagy by blocking the PAK1\/Akt Axis in breast Cancer. Cancer Res 76(15):4457\u20134469. https:\/\/doi.org\/10.1158\/0008-5472.Can-15-2887","journal-title":"Cancer Res"},{"issue":"6","key":"4695_CR20","first-page":"243","volume":"3","author":"H Hashimoto","year":"2009","unstructured":"Hashimoto H, Messerli SM, Sudo T, Maruta H (2009) Ivermectin inactivates the kinase PAK1 and blocks the PAK1-dependent growth of human ovarian cancer and NF2 tumor cell lines. Drug Discov Ther 3(6):243\u2013246","journal-title":"Drug Discov Ther"},{"key":"4695_CR21","doi-asserted-by":"publisher","first-page":"105207","DOI":"10.1016\/j.phrs.2020.105207","volume":"163","author":"M Tang","year":"2021","unstructured":"Tang M, Hu X, Wang Y, Yao X, Zhang W, Yu C et al (2021) Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacol Res 163:105207. https:\/\/doi.org\/10.1016\/j.phrs.2020.105207","journal-title":"Pharmacol Res"},{"issue":"4","key":"4695_CR22","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/j.1472-8206.2009.00684.x","volume":"23","author":"X Ci","year":"2009","unstructured":"Ci X, Li H, Yu Q, Zhang X, Yu L, Chen N et al (2009) Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway. Fundam Clin Pharmacol 23(4):449\u2013455. https:\/\/doi.org\/10.1111\/j.1472-8206.2009.00684.x","journal-title":"Fundam Clin Pharmacol"},{"issue":"06","key":"4695_CR23","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1017\/s1461145713001703","volume":"17","author":"L Asatryan","year":"2014","unstructured":"Asatryan L, Yardley MM, Khoja S, Trudell JR, Hyunh N, Louie SG et al (2014) Avermectins differentially affect ethanol intake and receptor function: implications for developing new therapeutics for alcohol use disorders. Int J Neuropsychopharmacol 17(06):907\u2013916. https:\/\/doi.org\/10.1017\/s1461145713001703","journal-title":"Int J Neuropsychopharmacol"},{"key":"4695_CR24","doi-asserted-by":"publisher","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","volume":"178","author":"L Caly","year":"2020","unstructured":"Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM (2020) The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 178:104787. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104787","journal-title":"Antiviral Res"},{"key":"4695_CR25","doi-asserted-by":"publisher","first-page":"106677","DOI":"10.1016\/j.bpc.2021.106677","volume":"278","author":"L Gonz\u00e1lez-Paz","year":"2021","unstructured":"Gonz\u00e1lez-Paz L, Hurtado-Le\u00f3n ML, Lossada C, Fern\u00e1ndez-Mater\u00e1n FV, Vera-Villalobos J, Loro\u00f1o M et al (2021) Comparative study of the interaction of ivermectin with proteins of interest associated with SARS-CoV-2: a computational and biophysical approach. Biophys Chem 278:106677. https:\/\/doi.org\/10.1016\/j.bpc.2021.106677","journal-title":"Biophys Chem"},{"issue":"7","key":"4695_CR26","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1097\/00001813-199609000-00005","volume":"7","author":"A Didier","year":"1996","unstructured":"Didier A, Loor F (1996) The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor. Anticancer Drugs 7(7):745\u2013751. https:\/\/doi.org\/10.1097\/00001813-199609000-00005","journal-title":"Anticancer Drugs"},{"key":"4695_CR27","doi-asserted-by":"publisher","first-page":"115071","DOI":"10.1016\/j.taap.2020.115071","volume":"401","author":"A Samy","year":"2020","unstructured":"Samy A, Bakthavachalam V, Vudutha M, Vinjamuri S, Chinnapaka S, Munirathinam G (2020) Eprinomectin, a novel semi-synthetic macrocylic lactone is cytotoxic to PC3 metastatic prostate cancer cells via inducing apoptosis. Toxicol Appl Pharmacol 401:115071. https:\/\/doi.org\/10.1016\/j.taap.2020.115071","journal-title":"Toxicol Appl Pharmacol"},{"issue":"4","key":"4695_CR28","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.cell.2009.06.034","volume":"138","author":"PB Gupta","year":"2009","unstructured":"Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA et al (2009) Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138(4):645\u2013659. https:\/\/doi.org\/10.1016\/j.cell.2009.06.034","journal-title":"Cell"},{"key":"4695_CR29","doi-asserted-by":"publisher","first-page":"104763","DOI":"10.1016\/j.phrs.2020.104763","volume":"156","author":"X Zhang","year":"2020","unstructured":"Zhang X, Zhang G, Zhai W, Zhao Z, Wang S, Yi J (2020) Inhibition of TMEM16A ca(2+)-activated Cl(-) channels by avermectins is essential for their anticancer effects. Pharmacol Res 156:104763. https:\/\/doi.org\/10.1016\/j.phrs.2020.104763","journal-title":"Pharmacol Res"},{"issue":"4613","key":"4695_CR30","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.6308762","volume":"221","author":"WC Campbell","year":"1983","unstructured":"Campbell WC, Fisher MH, Stapley EO, Albers-Sch\u00f6nberg G, Jacob TA (1983) Ivermectin: a potent new antiparasitic agent. Science 221(4613):823\u2013828. https:\/\/doi.org\/10.1126\/science.6308762","journal-title":"Science"},{"issue":"6499","key":"4695_CR31","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/371707a0","volume":"371","author":"DF Cully","year":"1994","unstructured":"Cully DF, Vassilatis DK, Liu KK, Paress PS, Van der Ploeg LH, Schaeffer JM et al (1994) Cloning of an avermectin-sensitive glutamate-gated chloride channel from Caenorhabditis elegans. Nature 371(6499):707\u2013711. https:\/\/doi.org\/10.1038\/371707a0","journal-title":"Nature"},{"issue":"6","key":"4695_CR32","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/j.1472-8206.2010.00896.x","volume":"25","author":"X Zhang","year":"2011","unstructured":"Zhang X, Li J, Chen C, Ci X, Yu Q, Zhang X et al (2011) Protective effect of abamectin on acute lung injury induced by lipopolysaccharide in mice. Fundam Clin Pharmacol 25(6):700\u2013707. https:\/\/doi.org\/10.1111\/j.1472-8206.2010.00896.x","journal-title":"Fundam Clin Pharmacol"},{"issue":"3","key":"4695_CR33","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.3892\/or.2018.6561","volume":"40","author":"D Song","year":"2018","unstructured":"Song D, Liang H, Qu B, Li Y, Liu J, Chen C et al (2018) Moxidectin inhibits glioma cell viability by inducing G0\/G1 cell cycle arrest and apoptosis. Oncol Rep 40(3):1348\u20131358. https:\/\/doi.org\/10.3892\/or.2018.6561","journal-title":"Oncol Rep"},{"key":"4695_CR34","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.chemosphere.2019.06.031","volume":"234","author":"Y Liang","year":"2019","unstructured":"Liang Y, Dong B, Pang N, Hu J (2019) ROS generation and DNA damage contribute to abamectin-induced cytotoxicity in mouse macrophage cells. Chemosphere 234:328\u2013337. https:\/\/doi.org\/10.1016\/j.chemosphere.2019.06.031","journal-title":"Chemosphere"},{"issue":"7","key":"4695_CR35","doi-asserted-by":"publisher","first-page":"e22336","DOI":"10.1002\/jbt.22336","volume":"33","author":"S Zhu","year":"2019","unstructured":"Zhu S, Zhou J, Zhou Z, Zhu Q (2019) Abamectin induces apoptosis and autophagy by inhibiting reactive oxygen species-mediated PI3K\/AKT signaling in MGC803 cells. J Biochem Mol Toxicol 33(7):e22336. https:\/\/doi.org\/10.1002\/jbt.22336","journal-title":"J Biochem Mol Toxicol"},{"issue":"12","key":"4695_CR36","doi-asserted-by":"publisher","first-page":"13726","DOI":"10.1007\/s11356-019-06869-2","volume":"27","author":"Y Liang","year":"2020","unstructured":"Liang Y, Dong B, Pang N, Hu J (2020) Abamectin induces cytotoxicity via the ROS, JNK, and ATM\/ATR pathways. Environ Sci Pollut Res Int 27(12):13726\u201313734. https:\/\/doi.org\/10.1007\/s11356-019-06869-2","journal-title":"Environ Sci Pollut Res Int"},{"issue":"8","key":"4695_CR37","doi-asserted-by":"publisher","first-page":"e22505","DOI":"10.1002\/jbt.22505","volume":"34","author":"S Zhu","year":"2020","unstructured":"Zhu S, Zhou J, Sun X, Zhou Z, Zhu Q (2020) ROS accumulation contributes to abamectin-induced apoptosis and autophagy via the inactivation of PI3K\/AKT\/mTOR pathway in TM3 leydig cells. J Biochem Mol Toxicol 34(8):e22505. https:\/\/doi.org\/10.1002\/jbt.22505","journal-title":"J Biochem Mol Toxicol"},{"issue":"1","key":"4695_CR38","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.cmet.2012.12.001","volume":"17","author":"B Faubert","year":"2013","unstructured":"Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z et al (2013) AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab 17(1):113\u2013124. https:\/\/doi.org\/10.1016\/j.cmet.2012.12.001","journal-title":"Cell Metab"},{"issue":"2","key":"4695_CR39","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/ncb2152","volume":"13","author":"J Kim","year":"2011","unstructured":"Kim J, Kundu M, Viollet B, Guan KL (2011) AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 13(2):132\u2013141. https:\/\/doi.org\/10.1038\/ncb2152","journal-title":"Nat Cell Biol"},{"issue":"15","key":"4695_CR40","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1128\/mcb.05565-11","volume":"31","author":"PJ Roach","year":"2011","unstructured":"Roach PJ (2011) AMPK -> ULK1 -> autophagy. Mol Cell Biol 31(15):3082\u20133084. https:\/\/doi.org\/10.1128\/mcb.05565-11","journal-title":"Mol Cell Biol"},{"key":"4695_CR41","doi-asserted-by":"crossref","unstructured":"Jang JE, Eom JI, Jeung HK, Cheong JW, Lee JY, Kim JS et al (2017) AMPK-ULK1-Mediated Autophagy confers resistance to BET inhibitor JQ1 in Acute myeloid leukemia stem cells. Clin Cancer Res 23(11):2781\u20132794. https:\/\/doi.org\/10.1158\/1078","DOI":"10.1158\/1078-0432.CCR-16-1903"},{"issue":"9","key":"4695_CR42","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.4161\/auto.29164","volume":"10","author":"CM Xie","year":"2014","unstructured":"Xie CM, Liu XY, Sham KW, Lai JM, Cheng CH (2014) Silencing of EEF2K (eukaryotic elongation factor-2 kinase) reveals AMPK-ULK1-dependent autophagy in colon cancer cells. Autophagy 10(9):1495\u20131508. https:\/\/doi.org\/10.4161\/auto.29164","journal-title":"Autophagy"},{"issue":"7","key":"4695_CR43","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1161\/RES.0b013e3182194c29","volume":"108","author":"K Mao","year":"2011","unstructured":"Mao K, Klionsky DJ (2011) AMPK activates autophagy by phosphorylating ULK1. Circ Res 108(7):787\u2013788. https:\/\/doi.org\/10.1161\/RES.0b013e3182194c29","journal-title":"Circ Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04695-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-024-04695-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04695-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T15:02:38Z","timestamp":1727535758000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-024-04695-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["4695"],"URL":"https:\/\/doi.org\/10.1007\/s00280-024-04695-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2024,9,5]]},"assertion":[{"value":"7 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were performed according to the guidelines approved by the Shanghai Medical Experimental Animal Care Commission.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}